Tiantan Biopharma advances blood disorder drug trial

Beijing Tiantan Biological Products Corp (SSE:600161) announced that its subsidiary, Chengdu Rong Sheng Pharmaceutical, will soon commence Phase III clinical trials for its "Human Coagulation Factor IX" drug, indicated for Hemophilia B (Factor IX deficiency). The drug has completed ethical review and pre-enrollment preparations. The company has invested 25.5766 million yuan into this research. While this is a positive step, the announcement notes that further procedures are required before commercialization, including completing the Phase III trial, submitting a marketing authorization application, and securing approvals from the National Medical Products Administration (NMPA). Competing products are already marketed by companies, including Shandong Taibang Biological Products and Grifols.